vTv Therapeutics Reports $6M Net Loss and Zero Revenue for Q2 2025

vTv Therapeutics Inc. reported its financial results for the quarter ended June 30, 2025, revealing a continued lack of revenue generation, with total revenue remaining at $0 for both the current and prior year periods. The company has not yet achieved profitability, posting a net loss attributable to common shareholders of $6.0 million for the three months ended June 30, 2025, compared to a loss of $5.2 million for the same period in 2024. For the six months ended June 30, 2025, the net loss attributable to common shareholders was $11.1 million, an increase from $10.0 million in the prior year.

Operating expenses for the second quarter of 2025 totaled $7.7 million, slightly higher than the $7.2 million reported in the same quarter of 2024. The increase was primarily driven by a rise in research and development expenses, which amounted to $4.1 million, up from $3.4 million in the previous year. General and administrative expenses decreased marginally to $3.6 million from $3.7 million. The company’s accumulated deficit reached $310.9 million as of June 30, 2025, reflecting its ongoing investment in drug development without corresponding revenue.

In terms of strategic developments, vTv Therapeutics has made significant progress in its clinical pipeline, particularly with cadisegliatin, which is currently in a Phase 3 trial for the treatment of type 1 diabetes. The company reinitiated patient screening for this trial in May 2025 and expects to have top-line data by the second half of 2026. Additionally, the U.S. Patent and Trademark Office has allowed claims covering the crystalline salt form of cadisegliatin, enhancing the company’s intellectual property portfolio.

Operationally, vTv Therapeutics has maintained a focus on its research and development activities, with total research and development expenses for the first half of 2025 amounting to $6.9 million, compared to $6.1 million in the same period of 2024. The company continues to evaluate various financing strategies to bolster its cash reserves, which stood at $25.9 million at the end of the reporting period. The company has indicated that it may pursue direct equity investments and potential licensing agreements to support its ongoing operations.

Looking ahead, vTv Therapeutics faces substantial challenges in securing additional funding to support its clinical trials and operational needs. The company has expressed concerns regarding its ability to continue as a going concern if it cannot raise sufficient capital. The management is actively exploring various financing options, including the potential monetization of its clinical development programs, to ensure the sustainability of its operations in the future.